Thursday, April 16, 2009

Wednesday, April 15, 2009

Autoimmune Disease? A step in the right direction for elimination


In essence like a heat seeking missle , if these selective modulators are directed at let us say hepatic eosinophyllic cell over-production there will be hope for AIH or Autoimmune Hepatitis,
Lupus (SLE), and other diseases involving autoimmunity, the disease can be eliminated.
There are cytokines which more specifically are responsible for the TNF and eosiniphyl and IgA
production. If their receptor is blocked then their action is blocked within the context of the cytokine cycle.

I will seek to continue to prove the connection of the Cytokine Cycle to the Krebs, Respriatory, UREA, and Glycolytic cycles as my contribution to humanity forever

Please read below for this GOOD NEWS!


http://bit.ly/p5QmB -For Twitters


Trial to Evaluate Safety of CCL2-LPM for Inflammatory Kidney Disease
SAN FRANCISCO, April 14 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., Inc. announced today that patient dosing has commenced in a Phase Ib clinical trial of the company's lead compound, CCL2-LPM, for the treatment of IgA nephropathy, an inflammatory kidney disease. Osprey Pharmaceuticals U.S.A. is developing novel chemokine-enzyme fusion protein therapeutics, known as Leukocyte Population Modulators (LPMs), for the treatment of inflammatory and autoimmune diseases. CCL2-LPM selectively targets activated leukocytes expressing the chemokine receptor CCR2 that are responsible for initiating and maintaining a variety of inflammatory conditions.
The Phase Ib open-label, dose-escalating study will enroll up to 30 patients diagnosed with IgA nephropathy at clinical sites in Canada. The trial design utilizes a continuous reassessment method to evaluate safety of CCL2-LPM and to establish a maximum-tolerated dose. Secondary endpoints for the Phase Ib clinical trial include an assessment of pharmacokinetics and biomarkers of disease associated with the mechanism of action of CCL2-LPM.
"We are pleased to advance the first of our LPM compounds designed to target and neutralize chemokine-mediated inflammation into clinical trials. CCL2-LPM has shown a favorable pharmaceutical profile, demonstrating efficacy at low doses in models of glomerulonephritis, as well as tolerability at relatively high doses in preclinical toxicology testing," said Barbara Finck, M.D, Senior Vice President of Research and Development and Chief Medical Officer for Osprey Pharmaceuticals U.S.A., Inc. "We are hopeful that the Phase Ib clinical trial of CCL2-LPM will provide us with indications of the compound's biologic activity in addition to establishing safety. Initial results from the Phase Ib study are expected later this year."

Tuesday, April 14, 2009

Tignons- Band of Angels

I always look forward to information on this because I have such an active following relative to this subject. The movie that surprised me to find more info wa my favorite, Band of Angels with Clark Gable from a Book by the same name. gable plays an x-Slave trader become slave plantation owner who is decent.
His mullato concubine wears a Tignon.
His new woman bought from Kentucky plantation never wears one!

Monday, April 13, 2009

VACCINES AS CURES?

http://42daysdailybread.blogspot.com/


Right Brain Scene (RBs)

Growths and Cancer and Abnormality Cures

Also speak to the problem

Saturday, April 11, 2009

Fooled Me this time

http://bit.ly/Emnkz



Look at the info and the SONG TITLE

Anthrax- No more Genocide?


A new statistical method that can estimate the origin and time of an aerosolized release of the pathogen causing anthrax, following detection of the first few cases has been developed by researchers from the Medical Research Council (MRC) Centre for Outbreak Analysis and Modelling at Imperial College London in collaboration with the Health Protection Agency's Microbial Risk Assessment group.
The method, described in an article published April 10 in the open-access journal PLoS Computational Biology, predicts where the most critically affected areas will be following the release of this highly pathogenic agent, which may enable preventative treatment of individuals at risk and protection from the disease.
Previously published methods can estimate the date and scale of anthrax release but not the source location or geographic extent of human exposure. The new method uses information about the first people infected, including when they started to experience symptoms of infection and where they live and work, combined with recent weather information, such as wind direction.
Dr Judith Legrand, lead author of the study from the MRC Centre for Outbreak Analysis and Modelling, said: "We have devised a new way to forecast the future course of a potential outbreak and the people and geographic areas likely to be worst affected."
Anthrax has the potential to cause a large number of deaths in the event of a covert, open air release. If such a release were to occur, it is critical for public health decision makers to evaluate its extent and the potential impact on the population and then to identify the people most at risk of infection as soon as possible.
Dr Judith Legrand added: "It is critical to treat people as soon as possible after exposure to anthrax. While forecasts based on small numbers of early cases are less reliable than those obtained later in an outbreak, we show that treating individuals based on early '/>"/>

Contact: Dr. Judith Legrandj.legrand@imperial.ac.uk44-781-206-5019Public Library of ScienceSource:Eurekalert

http://www.bio-medicine.org/biology-technology-1/Novel-method-predicts-impact-of-a-covert-anthrax-release-11466-1/

RED CAT REAL JAZZ-Darryl Lavigne

Darryl Lavigne - MUSIC ONLY

INCOME ONLINE-GOOD FLOW

http://www.incomedomination.com/makemoney.html

Clouds and Outsourcing

http://bit.ly/NDnvL

Friday, April 10, 2009

Isaiah 5:11 DO NOT be INFLAMED

Original Word
Word Origin

qld

a primitive root
Transliterated Word
Phonetic Spelling

Dalaq

daw-lak'
Parts of Speech
TWOT

Verb

435

KJV (9) - burning, 1; chase, 1; inflame, 1; kindle, 2; persecute, 1; persecutors, 1; pursue, 2;
NAS (9) - burning, 1; chased, 1; chasing, 1; fiery shafts, 1; hotly pursue, 1; hotly pursued, 1; inflame, 1; kindle, 1; set them on fire, 1;
01814
qld

From Bible Gateway
5:11
Woe to those who rise early in the morning that they may pursue strong drink, Who stay up late in the evening that wine may inflame them!

Tuesday, April 7, 2009

A Change is Going to Come

http://www.themarketguardian.com/2009/04/congressional-watchdog-to-drop-a-bombshell-on-the-us-financial-industry/


http://bit.ly/idPt0 For Twitters

Step in Right Direction

LELYSTAD, The Netherlands, April 6 /PRNewswire/ -- Today, Pepscan reports that it has achieved a major scientific breakthrough through the use of its CLIPS-based synthetic peptide immunogen technology. By constructing synthetic 3D mimics of the ligand binding-site on CXCR7 it has induced functional antibodies against the formerly intractable GPCR target CXCR7. CXCR7 is novel therapeutic target thought to be involved in tumor angiogenesis.

"We are proud and confident with achieving this major breakthrough!" says Professor Rob H. Meloen, Pepscan's founder and Chief Scientific officer. "Since a number of years we have been working on developing our CLIPS technology through which we can synthesize 3D conformational mimics of protein active sites , allowing us to do site-specific immunization to come up with functional antibodies against very difficult targets such as G-protein coupled receptors, as we have now proven with CXCR7." Meloen states that the CLIPS-technology is not limited to application in the GPCR field but also offers possibilities with other therapeutically interesting target such as for instance ion-channels.

Pepscan's Chief Commercial Officer Dr. Peter van Dijken thinks that this technology might unlock a whole new area of interesting therapeutic targets that could so far not be addressed: "One-third of the interesting GPCR targets have proven to be "undrugable" until now. Our CLIPS technology provides a systematic and efficient way to unlock these targets and make them available to antibody therapy, that is a multi-billion dollar playing field to which Pepscan now holds the unique technological key!"

Pepscan indicated today that over the coming period, it will continue to technically and commercially develop its clips-based technology for additional targets and indications.

Therapeutic antibody therapy is well established. Monoclonal antibodies are produced outsid
'/>"/>


SOURCE Pepscan Therapeutics B.V.
Copyright©2009 PR Newswire.
All rights reserved

Definite Strategic Collaboration

BEIJING, April 6 /PRNewswire/ -- BioDuro announced today that they have entered into a strategic partnership with Roche to support discovery phase research efforts at Roche's global research sites. BioDuro will provide research services in the areas of discovery chemistry and biology, which can help to shorten (internal) drug discovery timelines. This agreement is an expansion of an existing relationship.
Roche has many years of experience in partnering with external companies to complement its internal drug discovery expertise with external services and innovation. After extensive evaluation of many companies, Roche selected BioDuro as a strategic partner for this effort.
"Presently, there is intense competition within the CRO industry for outsourcing and drug discovery services, and the expectation is that they will deliver problem solving skills and innovation in both chemistry and biology," commented Robert Goodnow, Ph.D., Roche's Global Head of Medicinal Chemistry Outsourcing. "We selected BioDuro due to their demonstrated excellent performance in synthetic chemistry and ability to deliver integrated medicinal chemistry services."
"BioDuro is pleased to build upon this existing collaboration and work closely with the experienced team at Roche to aid in the development of novel therapeutics. We care deeply about working on projects that will impact the quality of life worldwide and working with Roche ensures this outcome. Our partnership demonstrates the strength of our innovative, fully integrated R&D service platform, and is a true testament to the caliber of scientists that have joined our team," commented John Oyler, Chief Executive Officer and co-founder of BioDuro LLC.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's bigges'/>"/>

SOURCE BioDuroCopyright©2009 PR Newswire.All rights reserved

Sunday, April 5, 2009

Updates by minute

http://bit.ly/196omj
You may like my summary

Jacky

http://www.reverbnation.com/jacquelineofficial

Hit her up Make Aussies happy

Sleazy I do not think so

http://online.wsj.com/article/SB123879833094588163.html

Nothing can get more sleazy than bringing forth a financial breakdown of the entire
world community for the Tri-Lateral commission, then wishing him GOOD LUCK

The fact of the matter is that the controllers of the banks in the past are the ones that got us in the mess in the first place. It can not get any worst when the 700 Billion already given to the
x-president's retirement fund is remaining stagnant and AIG is asking for more. be part of the soloution of positive. We know it is a Ruppert stimulated post in the WSJ, from the divide and conquer "continentals"

Read this instead on Twitter
waynesutton 2 other Triangle Startup weekend startups in private beta: @startupjunkyard http://startupjunkyard.com & @tribetrader http://tribetrader.com

IBM says We'll take this deal and SHOVE IT

from
I.B..M. Withdraws $7 Billion Offer for Sun Microsystems

http://www.nytimes.com/2009/04/06/technology/business-computing/06blue.html?_r=1&hp


@JRStratford http://ping.fm/emr9S Please RT
REVIEW
The breakdown in the talks, said the second person close to the negotiations, came over the shifting balance of price and conditions for the deal.
For example, I.B.M. scrutinized the "change of control" contracts with Sun executives, senior engineers and managers. I.B.M. felt that the payments to senior employees were higher and extended more broadly across the company than it had anticipated. I.B.M. pointed to the change of control contracts as one reason it was reducing its offer price.

Also look at
http://www.anewworldforum.com/viewtopic.php?f=14&t=776

This was comical

Saturday, April 4, 2009

Lab in China

ROCHESTER, N.Y., YORK, England and BETHESDA, Md., April 1 /PRNewswire-Asia/ -- ACM Global Central Laboratory, the laboratory that continually defines the client-service standard with its inherently flexible approach, and Chindex International, Inc. (Nasdaq: CHDX), today announced a partnership to provide central lab services in China at United Family Hospitals, Beijing (UFH). UFH is a CAP-certified facility owned by Chindex International, Inc.
ACM Global Central Laboratory conducted a harmonization program in China, and chose to work with Chindex in order to ensure the same degree of global standards that clients enjoy from the Americas, Europe, India and Australasia. Offering on-the-ground central lab capabilities in China is a significant milestone in the organization's history.
"Given the challenges of exporting whole blood from Mainland China coupled with the demand for conducting trials in China, we recognized the importance of establishing services locally," said Elena Logan, Vice President, ACM Global Central Laboratory. "We also refuse to compromise on quality and working with Chindex helps us maintain our rigorous service standards in an exciting developing market. I'm honored to be able to work with the UFH team led by US trained pathologist, Dr. Sun Fei, who will oversee the clinical trial efforts at UFH."
"As the only Western-founded hospital lab in Beijing, and the only JCI accredited hospital in China with CAP accreditation, UFH is well-poised to provide unparalleled central lab services. Working with a global leader like ACM acknowledges our unique competitive position as well as our dedication to high standards of care. We also look forward to providing additional diagnostic testing to the local community through this partnership," said Roberta Lipson, CEO of Chindex.